SCHEMBL16631175

SCHEMBL16631175

C#Cc1[nH]c(=O)cc(F)c1[C@@H]1O[C@H](CO)C(O)[C@@H]1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDA P32320 1/20 0.35
LMNA P02545 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
SLC28A1 O00337 1/20 0.32
SLC28A2 O43868 1/20 0.32
SLC29A1 Q99808 1/20 0.32
SLC28A3 Q9HAS3 1/20 0.32
B4GALT1 P15291 1/20 0.31
P2RY14 Q15391 1/20 0.31
SLC5A2 P31639 3/20 0.31
SLC5A1 P13866 1/20 0.31
SYNJ2 O15056 1/20 0.31
KDM4E B2RXH2 1/20 0.31
GMNN O75496 1/20 0.31
MAPT P10636 1/20 0.31
BLM P54132 1/20 0.31
PMP22 Q01453 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631241 0.91 SYNJ2 (0.38) LMNASMN1; SMN2SLC28A1SLC28A2SLC29A1
SCHEMBL18079916 0.86 CDA (0.34) CDALMNASLC28A1SLC28A2SLC29A1
SCHEMBL16631598 0.84 LGALS3 (0.35) LMNAB4GALT1P2RY14SLC5A2TSHR
SCHEMBL16631249 0.84 CDA (0.38) CDALMNASMN1; SMN2SLC28A1SLC28A2
SCHEMBL16631196 0.83 TSHR (0.33) LMNASMN1; SMN2MAPTPMP22TSHR
SCHEMBL16631251 0.82 CDA (0.37) CDALMNASLC28A1SLC28A2SLC29A1
SCHEMBL16631173 0.79 SLC28A1 (0.38) CDALMNASMN1; SMN2SLC28A1SLC28A2
SCHEMBL16631840 0.78 CDA (0.32) CDASYNJ2
SCHEMBL16631255 0.77 SYNJ2 (0.39) LMNASMN1; SMN2SLC28A1SLC28A2SLC29A1
SCHEMBL16631174 0.77 PYGL (0.35) CDASLC28A1SLC28A2SLC29A1SLC28A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 CDA 200/4885LMNA 776/4885SMN1; SMN2 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.